RA
IONS icon

Reby Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Reby Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$11K Buy
+200
New +$9.97K ﹤0.01% 415

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Reby Advisors's IONS Position: Q4 2020 in Review

Reby Advisors opened a new position in Ionis Pharmaceuticals (IONS) in Q4 2020: 200 shares worth $11K. The stake represents ﹤0.01% of the portfolio and ranks #415 among its holdings.

382 funds tracked by Wall St. Rank hold IONS as of Q4 2020.

  • Reby Advisors held 200 shares of Ionis Pharmaceuticals worth $11K as of Q4 2020.
  • Ionis Pharmaceuticals was a new Reby Advisors position in Q4 2020.
  • Ionis Pharmaceuticals made up ﹤0.01% of Reby Advisors's portfolio in Q4 2020, its #415 holding.
  • 382 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2020.

Based on Reby Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.